- Headline data reported from patients enrolled in completed Part I and ongoing Part II of MATINS study
- Strongest disease control rate (DCR) of 31% seen in cutaneous melanoma, gastric cancer and cholangiocarcinoma patients
- 100% six-month survival rate observed in DCR patients compared with 31.1 % for non-DCR patients
- Equivalent prior treatment durations for DCR and non-DCR patients suggests DCR with bexmarilimab is indicator of anti-tumour activity and survival benefit
Marku stated SSV window lasted until April 24th - if memory serves me correct. This statement was made long before the farce with the Solidarity Trial.
A couple of solid RNS then we could be back upto the £5 region. But like i’ve said before the only way this will get major traction is if we get confirmed partners onboard.